Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1990 May;45(5):377–381. doi: 10.1136/thx.45.5.377

Effect of inhaled frusemide on the early response to antigen and subsequent change in airway reactivity in atopic patients.

P Verdiani 1, S Di Carlo 1, A Baronti 1, S Bianco 1
PMCID: PMC462479  PMID: 2382243

Abstract

The purpose of this study was to investigate whether inhaled frusemide was able to inhibit the increase in nonspecific bronchial reactivity that occurs after the early response to allergen exposure in subjects with allergic rhinitis or asthma (or both). Ten symptom free patients initially underwent a challenge with methacholine, to determine the dose of methacholine that caused a 15% fall in FEV1 (PD15 FEV1 meth) and a challenge with a specific allergen, to determine the concentration of allergen that caused a fall in FEV1 of at least 15%. On two further occasions they inhaled allergen concentration that had caused the greater than or equal to 15% fall in FEV1 preceded by inhaled frusemide (40 mg frusemide in 4 ml buffered saline) or placebo (4 ml of diluent solution), according to a randomised, double blind, crossover design. All allergen studies were separated by at least seven days. A methacholine challenge was performed two hours after the allergen challenge, a time when the early response to allergen had completely resolved. Frusemide inhibited the early response to antigen, causing mean (95% confidence interval) protection of 87.6% (96-80%) for the maximum fall in FEV1. The increase in non-specific airway reactivity that occurred after antigen when this was preceded by placebo was reduced by frusemide. The mean (95% CI) difference in PD15 values between the placebo and the frusemide days was 1.73 (2.30-1.16) doubling doses of methacholine. These results confirm that frusemide is highly effective in preventing the early response to allergen, and show that it inhibits the increase in reactivity to methacholine that follows the early response.

Full text

PDF
377

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianco S., Pieroni M. G., Refini R. M., Rottoli L., Sestini P. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med. 1989 Oct 19;321(16):1069–1073. doi: 10.1056/NEJM198910193211602. [DOI] [PubMed] [Google Scholar]
  2. Bianco S., Vaghi A., Robuschi M., Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet. 1988 Jul 30;2(8605):252–255. doi: 10.1016/s0140-6736(88)92540-8. [DOI] [PubMed] [Google Scholar]
  3. Chapman H. A., Jr, Reilly J. J., Jr, Kobzik L. Role of plasminogen activator in degradation of extracellular matrix protein by live human alveolar macrophages. Am Rev Respir Dis. 1988 Feb;137(2):412–419. doi: 10.1164/ajrccm/137.2.412. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W. Mechanism of perennial allergic asthma. Lancet. 1983 Jul 30;2(8344):253–256. doi: 10.1016/s0140-6736(83)90235-0. [DOI] [PubMed] [Google Scholar]
  5. Cookson W. O., Craddock C. F., Benson M. K., Durham S. R. Falls in peripheral eosinophil counts parallel the late asthmatic response. Am Rev Respir Dis. 1989 Feb;139(2):458–462. doi: 10.1164/ajrccm/139.2.458. [DOI] [PubMed] [Google Scholar]
  6. Eggleston P. A., Kagey-Sobotka A., Schleimer R. P., Lichtenstein L. M. Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis. 1984 Jul;130(1):86–91. doi: 10.1164/arrd.1984.130.1.86. [DOI] [PubMed] [Google Scholar]
  7. Holgate S. T., Hardy C., Robinson C., Agius R. M., Howarth P. H. The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol. 1986 Feb;77(2):274–282. doi: 10.1016/s0091-6749(86)80104-x. [DOI] [PubMed] [Google Scholar]
  8. Larsen G. L. Late-phase reactions: observations on pathogenesis and prevention. J Allergy Clin Immunol. 1985 Nov;76(5):665–669. doi: 10.1016/0091-6749(85)90668-2. [DOI] [PubMed] [Google Scholar]
  9. Olver R. E., Davis B., Marin M. G., Nadel J. A. Active transport of Na+ and Cl- across the canine tracheal epithelium in vitro. Am Rev Respir Dis. 1975 Dec;112(6):811–815. doi: 10.1164/arrd.1975.112.6.811. [DOI] [PubMed] [Google Scholar]
  10. Silber G., Proud D., Warner J., Naclerio R., Kagey-Sobotka A., Lichtenstein L., Eggleston P. In vivo release of inflammatory mediators by hyperosmolar solutions. Am Rev Respir Dis. 1988 Mar;137(3):606–612. doi: 10.1164/ajrccm/137.3.606. [DOI] [PubMed] [Google Scholar]
  11. Thorpe J. E., Steinberg D., Bernstein I. L., Murlas C. G. Bronchial reactivity increases soon after the immediate response in dual-responding asthmatic subjects. Chest. 1987 Jan;91(1):21–25. doi: 10.1378/chest.91.1.21. [DOI] [PubMed] [Google Scholar]
  12. Welsh M. J. Inhibition of chloride secretion by furosemide in canine tracheal epithelium. J Membr Biol. 1983;71(3):219–226. doi: 10.1007/BF01875463. [DOI] [PubMed] [Google Scholar]
  13. Wenzel S. E., Fowler A. A., 3rd, Schwartz L. B. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis. 1988 May;137(5):1002–1008. doi: 10.1164/ajrccm/137.5.1002. [DOI] [PubMed] [Google Scholar]
  14. Widdicombe J. H. Ion transport by tracheal epithelial cells in culture. Clin Chest Med. 1986 Jun;7(2):299–305. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES